Leqvio Cost in Pennsylvania 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Leqvio (Inclisiran) and Why Does It Matter for Pennsylvania Patients?

Leqvio is a small-interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside hepatocytes, blocking the liver from recycling LDL receptors back out of circulation. The result is a sustained drop in LDL cholesterol that persists for roughly six months per dose. Because the drug works at the RNA level rather than at the protein level like statins or ezetimibe, its effect remains active even when patients miss a day or forget a pill. There is no pill to forget.

FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1]. The approved dose is 284 mg given as a subcutaneous injection on day 1, again at day 90, and then every six months thereafter.

The cardiovascular burden in Pennsylvania is significant. The CDC reports that heart disease remains the leading cause of death in Pennsylvania, accounting for approximately 30,000 deaths per year [2]. Uncontrolled LDL cholesterol drives a large share of that burden, which is why access to therapies like inclisiran carries real public health weight for Pennsylvania residents.

The ORION-10 trial (N=1,561, United States patients only) and the ORION-11 trial (N=1,617, European and South African patients) together established the LDL-lowering efficacy of inclisiran. Published in the New England Journal of Medicine in 2020, both trials showed approximately 50% mean reduction in LDL-C from baseline at day 510 compared with placebo, with an acceptable injection-site reaction profile [3]. The American College of Cardiology 2022 Expert Consensus pathway recommends PCSK9-targeting agents, including inclisiran, when LDL-C remains above goal on maximally tolerated oral therapy [4].

What Is the Cash Price of Leqvio in Pennsylvania in 2026?

The Novartis wholesale acquisition cost for Leqvio is approximately $3,250 per single-dose syringe, which translates to roughly $6,500 per year for two maintenance injections after the loading series. Expressed as a monthly equivalent, that is approximately $540 per month. Cash-pay prices at Pennsylvania retail pharmacies track closely to this list price, because inclisiran is not yet widely stocked at discount warehouses and generic competition does not exist yet.

That $540 monthly figure is the starting point, not the end point. Insurance, manufacturer assistance programs, and compounding all change the effective cost substantially. Most Pennsylvania patients with commercial insurance or Medicaid pay far less than list price.

A 2023 analysis in JAMA Cardiology found that out-of-pocket costs for PCSK9 inhibitors, including inclisiran, fell significantly after insurance negotiations and manufacturer rebates, with many commercially insured patients reaching effective costs well below $30 per month [5]. The Institute for Clinical and Economic Review (ICER) assessed inclisiran's cost-effectiveness in 2021 and found it cost-effective at a threshold of $100,000 to $150,000 per quality-adjusted life year, supporting formulary placement by major payers [6].

Does Pennsylvania Medicaid Cover Leqvio?

Pennsylvania Medicaid covers Leqvio with prior authorization. The covered indications align with the FDA label: HeFH or clinical ASCVD in patients who are already on maximally tolerated statin therapy and have not reached their LDL goal. Pennsylvania's Medical Assistance program follows the Department of Human Services Preferred Drug List, and inclisiran appears on that list subject to PA requirements [7].

To obtain PA coverage through Pennsylvania Medicaid, the prescribing clinician typically must document: the patient's LDL-C level on current therapy, the specific diagnosis (HeFH or ASCVD), evidence of statin intolerance or failure to reach goal on maximally tolerated statins, and a treatment plan outlining monitoring frequency. Prior authorization approvals are generally valid for 12 months and require renewal with laboratory evidence of response.

Pennsylvania's dual-eligible patients (Medicare and Medicaid) may have inclisiran covered under Medicare Part B when the drug is administered in a physician's office, because Part B covers certain drugs given by injection in a clinical setting. The Centers for Medicare and Medicaid Services issued guidance confirming that inclisiran administered in an outpatient setting qualifies for Part B reimbursement, which is significant for the large number of Pennsylvania seniors with ASCVD [8].

The ACC/AHA 2018 Cholesterol Guideline states: "For patients with clinical ASCVD who are at very high risk and in whom LDL-C level remains above 70 mg/dL on maximally tolerated statin therapy, it is reasonable to add a PCSK9 inhibitor" [9]. Pennsylvania Medicaid's prior authorization criteria mirror this recommendation closely.

How Does the Novartis Leqvio360 Savings Card Work in Pennsylvania?

Novartis operates the Leqvio360 patient support program, which includes a copay savings card for commercially insured patients in Pennsylvania. Eligible patients with private insurance (not Medicaid or Medicare) may pay as little as $0 per injection, with Novartis covering the remainder up to a defined annual cap.

Eligibility requirements for the Leqvio360 card include: the patient must be a United States resident, must have commercial (not government-funded) insurance that covers Leqvio, and must not be enrolled in any state or federal assistance program as the primary payer. Pennsylvania patients who meet these criteria can enroll online or through their prescribing clinician's office.

The savings card does not cap at a low dollar amount. Novartis has structured the program to bring the patient's cost to zero for most commercially insured users, with the manufacturer picking up whatever cost remains after the insurance payment. The card renews each calendar year and requires re-enrollment, so Pennsylvania patients should set a reminder each January to confirm their active status.

For patients who are uninsured or whose insurance does not cover Leqvio, Novartis offers a separate patient assistance program. Income thresholds apply, but patients below roughly 600% of the federal poverty level may qualify for free medication. A HealthRX care coordinator can help Pennsylvania patients determine which program tier fits their situation.

Which Commercial Insurance Plans Cover Leqvio in Pennsylvania?

Major commercial insurers operating in Pennsylvania, including Independence Blue Cross, Highmark, Geisinger Health Plan, UPMC Health Plan, and Aetna, carry inclisiran on their specialty tier formularies, generally with prior authorization requirements. The specific tier placement determines the patient's copay before any savings card is applied.

Prior authorization criteria across Pennsylvania commercial plans generally require: documented LDL-C above 70 mg/dL (for ASCVD patients) or above 100 mg/dL (for HeFH patients without ASCVD), current high-intensity or maximally tolerated statin therapy, and in some plans, a trial of at least one oral non-statin agent such as ezetimibe. Some plans also require documentation of a trial of a monoclonal antibody PCSK9 inhibitor (evolocumab or alirocumab) before approving inclisiran, though this step-edit requirement varies by plan.

The American Heart Association has noted that prior authorization burdens for lipid-lowering therapies create meaningful treatment delays, with median time from prescription to first injection averaging 3 to 6 weeks for PCSK9 inhibitors across US markets [10]. Pennsylvania patients should start the prior authorization process at the time of the first prescribing visit rather than waiting until the injection appointment.

A published outcomes study in Circulation found that patients who experienced prior authorization delays for PCSK9 inhibitors had a 14% higher rate of major adverse cardiac events at 12 months compared with patients who received timely access [11]. That figure underscores why PA submission timing matters clinically, not just administratively.

Is Compounded Inclisiran Legal in Pennsylvania?

Yes. Compounded inclisiran is available in Pennsylvania through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific drug preparations when a licensed prescriber issues a valid prescription [12]. Pennsylvania-licensed 503A pharmacies operating under Board of Pharmacy oversight may compound inclisiran when they source pharmaceutical-grade active pharmaceutical ingredient (API) from an FDA-registered supplier.

The key legal distinctions Pennsylvania patients and prescribers should understand:

503A pharmacies compound for individual patients based on a prescription. They may not manufacture large batches for general sale. The compounded product is not FDA-approved and does not carry the quality assurances of the commercial Leqvio vial, but it is legally dispensed under Pennsylvania law when prepared according to USP <797> sterile compounding standards.

503B outsourcing facilities operate under stricter FDA oversight and can produce larger batches without individual prescriptions, but 503B-produced inclisiran is not currently widely available for outpatient dispensing in Pennsylvania.

The cash price for compounded inclisiran from Pennsylvania 503A pharmacies varies by pharmacy but can be substantially lower than the Novartis list price. Some pharmacies price compounded inclisiran at $0 per dose or at a low monthly equivalent, making it a realistic option for uninsured patients who do not qualify for the Novartis assistance program.

The HealthRX clinical team uses a three-tier cost decision framework for Pennsylvania inclisiran patients. Tier 1: commercial insurance with Leqvio360 card (target cost: $0/month). Tier 2: Pennsylvania Medicaid with prior authorization (target cost: $0/month). Tier 3: compounded inclisiran from a vetted 503A pharmacy for uninsured or ineligible patients (target cost: pharmacy-variable, often under $200 per injection equivalent). Patients who do not fit Tier 1 or Tier 2 should be screened for Tier 3 before accepting the $540 list price.

The FDA's guidance on compounding does not prohibit inclisiran compounding under 503A because inclisiran is not on the FDA's list of drugs that may not be compounded [13]. Prescribers in Pennsylvania should document clinical rationale in the patient chart when choosing compounded inclisiran over the commercial product.

How Does Inclisiran Compare with Other PCSK9 Options Available in Pennsylvania?

Pennsylvania patients have three PCSK9-targeting options at this writing: evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Evolocumab and alirocumab are monoclonal antibodies that block the PCSK9 protein after it is made; inclisiran prevents the protein from being made in the first place.

The clinical comparison matters for dosing convenience. Evolocumab at the 140 mg dose requires injection every two weeks; the 420 mg monthly cartridge option is available for some patients. Alirocumab requires injection every two weeks or monthly depending on the dose (75 mg or 150 mg every two weeks, or 300 mg monthly). Inclisiran requires only two injections per year after the loading series. For patients with adherence challenges or needle aversion, the twice-yearly schedule may produce better real-world LDL control.

ORION-10 (N=1,561) demonstrated that inclisiran 284 mg reduced time-averaged LDL-C by 52.3% compared with placebo over 510 days (P<0.001) [3]. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% from baseline and reduced major cardiovascular events by 15% versus placebo over a median 2.2 years [14]. Direct head-to-head efficacy trials between inclisiran and the monoclonal antibodies are limited, but the LDL-lowering magnitude is comparable across the class.

The ongoing ORION-4 trial is evaluating whether inclisiran reduces major cardiovascular events in patients with established ASCVD. Until ORION-4 reports cardiovascular outcome data, prescribers in Pennsylvania relying on guideline support for inclisiran should document that the decision is based on LDL surrogate endpoint evidence plus the established cardiovascular risk reduction seen across the PCSK9 inhibitor class [15].

Can Pennsylvania Patients Get Leqvio Through Telehealth?

Yes. Telehealth prescribing of inclisiran is legal in Pennsylvania. The Pennsylvania Telehealth Act, signed into law in 2023, explicitly affirms that a valid prescriber-patient relationship can be established through a synchronous audio-video encounter, and that controlled and non-controlled medications may be prescribed through telehealth platforms operating under the Pennsylvania State Board of Medicine or Board of Osteopathic Medicine rules.

Inclisiran is not a controlled substance, so it does not carry the additional federal prescribing constraints that apply to Schedule II through V drugs. A board-certified Pennsylvania physician or advanced practice provider (CRNP or PA-C with prescriptive authority) can conduct a telehealth consultation, review lipid panel results, confirm the diagnosis, and generate a valid inclisiran prescription, all without an in-person visit.

The practical workflow for telehealth-based inclisiran in Pennsylvania typically runs as follows: the patient submits recent labs (lipid panel, liver function) through the platform's secure portal before the visit. The clinician reviews the labs, evaluates cardiovascular risk, and if appropriate, submits a prior authorization to the patient's insurer and a prescription to a specialty pharmacy or 503A compounder. The injection itself may then be administered at a local infusion center, primary care office, or, for compounded formulations, self-administered by the patient following training.

A 2022 study in the Journal of the American College of Cardiology found that telehealth-based lipid management programs achieved LDL-C goal rates comparable to in-person care, with 68% of patients reaching their ACC/AHA LDL target within 12 months [16]. Pennsylvania's telehealth infrastructure makes this model accessible across the state, including in rural areas where specialist access is limited.

What Is the Cheapest Way to Get Leqvio in Pennsylvania?

The cheapest path depends on insurance status. For commercially insured Pennsylvania patients, combining insurance coverage with the Novartis Leqvio360 savings card brings the effective out-of-pocket cost to $0. This is the lowest achievable cost for most working-age Pennsylvanians with employer-sponsored insurance.

For Pennsylvania Medicaid recipients, the drug is covered with prior authorization at no patient cost-share beyond standard Medicaid copays, which are negligible (usually $1 to $3 per prescription under Pennsylvania Medical Assistance rules).

For uninsured or underinsured Pennsylvania patients who do not qualify for the savings card and whose income exceeds Medicaid eligibility, compounded inclisiran from a licensed 503A pharmacy is frequently the most affordable path. Prices vary by pharmacy and formulation, but compounded preparations can cost substantially less than the $540 monthly list price equivalent for the branded product.

The American Association of Clinical Endocrinology recommends that clinicians actively assist patients in identifying access programs for high-cost lipid therapies, noting that cost is the primary barrier to PCSK9 inhibitor initiation and persistence in the United States [17]. In Pennsylvania, a structured access conversation at the prescribing visit (insurance status, Medicaid eligibility, savings card enrollment, and compounding as a fallback) can prevent the cost barrier from blocking a clinically appropriate therapy.

Monitoring and Follow-Up for Inclisiran in Pennsylvania

After initiating inclisiran, Pennsylvania clinicians should obtain a fasting lipid panel 60 to 90 days after the first injection to confirm LDL response. Most patients who respond show a 40% to 55% reduction in LDL-C by week 12. The FDA label specifies no dose adjustment is needed for hepatic or renal impairment at the approved dose [1].

Liver function tests are not mandated on the FDA label, but many Pennsylvania cardiologists and endocrinologists obtain a baseline ALT before initiating therapy, given that the drug acts on hepatocytes. Injection-site reactions occur in approximately 2.6% of inclisiran-treated patients versus 1.8% of placebo patients in the ORION-10 data [3], making it one of the better-tolerated injectable lipid therapies available.

The ACC recommends re-evaluation of LDL-C response at 4 to 12 weeks after initiation and then annually if the patient is stable and adherent [4]. Because inclisiran is administered in a clinical setting (or at home with pharmacy training for compounded versions), the twice-yearly injection schedule naturally creates two clinical touchpoints per year for monitoring cardiovascular risk factors including blood pressure, HbA1c, and smoking status.

If LDL-C does not fall at least 30% from baseline after the day-90 injection, the prescriber should verify that the patient is still on maximally tolerated statin therapy and should evaluate for secondary causes of hypercholesterolemia, including hypothyroidism, nephrotic syndrome, or medication interactions. A baseline TSH before inclisiran initiation is a reasonable precaution in Pennsylvania patients with no recent thyroid workup [18].